vs
Ginkgo Bioworks Holdings, Inc.（DNA）与RBB Bancorp（RBB）财务数据对比。点击上方公司名可切换其他公司
Ginkgo Bioworks Holdings, Inc.的季度营收约是RBB Bancorp的1.0倍（$33.4M vs $32.3M），RBB Bancorp同比增速更快（12.6% vs -23.8%），RBB Bancorp自由现金流更多（$42.6M vs $-47.7M），过去两年RBB Bancorp的营收复合增速更高（7.0% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
RBB银行控股公司是总部位于美国的金融控股集团，旗下核心主体为皇家商业银行，主要服务亚裔社群、中小微企业、不动产投资者及零售客户，提供商业信贷、储蓄存款、财富管理等多元金融服务，业务覆盖美国沿海核心都会区。
DNA vs RBB — 直观对比
营收规模更大
DNA
是对方的1.0倍
$32.3M
营收增速更快
RBB
高出36.4%
-23.8%
自由现金流更多
RBB
多$90.3M
$-47.7M
两年增速更快
RBB
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $32.3M |
| 净利润 | — | $10.2M |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 39.5% |
| 净利率 | — | 31.5% |
| 营收同比 | -23.8% | 12.6% |
| 净利润同比 | — | 132.1% |
| 每股收益（稀释后） | $-1.41 | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNARBB
| Q4 25 | $33.4M | $32.3M | ||
| Q3 25 | $38.8M | $32.6M | ||
| Q2 25 | $49.6M | $35.8M | ||
| Q1 25 | $48.3M | $28.5M | ||
| Q4 24 | $43.8M | $28.7M | ||
| Q3 24 | $89.0M | $30.3M | ||
| Q2 24 | $56.2M | $27.5M | ||
| Q1 24 | $37.9M | $28.2M |
净利润DNARBB
| Q4 25 | — | $10.2M | ||
| Q3 25 | $-80.8M | $10.1M | ||
| Q2 25 | $-60.3M | $9.3M | ||
| Q1 25 | $-91.0M | $2.3M | ||
| Q4 24 | — | $4.4M | ||
| Q3 24 | $-56.4M | $7.0M | ||
| Q2 24 | $-217.2M | $7.2M | ||
| Q1 24 | $-165.9M | $8.0M |
营业利润率DNARBB
| Q4 25 | -211.9% | 39.5% | ||
| Q3 25 | -231.8% | 40.7% | ||
| Q2 25 | -132.1% | 36.1% | ||
| Q1 25 | -184.1% | 11.2% | ||
| Q4 24 | -236.3% | 17.6% | ||
| Q3 24 | -62.0% | 31.6% | ||
| Q2 24 | -396.7% | 35.6% | ||
| Q1 24 | -469.1% | 39.9% |
净利率DNARBB
| Q4 25 | — | 31.5% | ||
| Q3 25 | -207.9% | 31.2% | ||
| Q2 25 | -121.6% | 26.1% | ||
| Q1 25 | -188.2% | 8.0% | ||
| Q4 24 | — | 15.3% | ||
| Q3 24 | -63.3% | 23.1% | ||
| Q2 24 | -386.4% | 26.4% | ||
| Q1 24 | -437.3% | 28.4% |
每股收益（稀释后）DNARBB
| Q4 25 | $-1.41 | $0.59 | ||
| Q3 25 | $-1.45 | $0.59 | ||
| Q2 25 | $-1.10 | $0.52 | ||
| Q1 25 | $-1.68 | $0.13 | ||
| Q4 24 | $-1.91 | $0.26 | ||
| Q3 24 | $-1.08 | $0.39 | ||
| Q2 24 | $-4.23 | $0.39 | ||
| Q1 24 | $-3.32 | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $212.3M |
| 总债务越低越好 | — | $119.9M |
| 股东权益账面价值 | $508.6M | $523.4M |
| 总资产 | $1.1B | $4.2B |
| 负债/权益比越低杠杆越低 | — | 0.23× |
8季度趋势，按日历期对齐
现金及短期投资DNARBB
| Q4 25 | $422.6M | $212.3M | ||
| Q3 25 | $495.5M | $234.9M | ||
| Q2 25 | $559.4M | $191.9M | ||
| Q1 25 | $325.3M | $238.8M | ||
| Q4 24 | $561.6M | $257.7M | ||
| Q3 24 | $616.2M | $349.4M | ||
| Q2 24 | $730.4M | $252.8M | ||
| Q1 24 | $840.4M | — |
总债务DNARBB
| Q4 25 | — | $119.9M | ||
| Q3 25 | — | $119.8M | ||
| Q2 25 | — | $119.7M | ||
| Q1 25 | — | $119.6M | ||
| Q4 24 | — | $119.5M | ||
| Q3 24 | — | $119.4M | ||
| Q2 24 | — | $119.3M | ||
| Q1 24 | — | $119.2M |
股东权益DNARBB
| Q4 25 | $508.6M | $523.4M | ||
| Q3 25 | $559.8M | $514.3M | ||
| Q2 25 | $613.0M | $517.7M | ||
| Q1 25 | $647.4M | $510.3M | ||
| Q4 24 | $716.1M | $507.9M | ||
| Q3 24 | $797.9M | $509.7M | ||
| Q2 24 | $833.1M | $511.3M | ||
| Q1 24 | $987.3M | $514.0M |
总资产DNARBB
| Q4 25 | $1.1B | $4.2B | ||
| Q3 25 | $1.2B | $4.2B | ||
| Q2 25 | $1.2B | $4.1B | ||
| Q1 25 | $1.3B | $4.0B | ||
| Q4 24 | $1.4B | $4.0B | ||
| Q3 24 | $1.5B | $4.0B | ||
| Q2 24 | $1.6B | $3.9B | ||
| Q1 24 | $1.6B | $3.9B |
负债/权益比DNARBB
| Q4 25 | — | 0.23× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 0.23× | ||
| Q1 25 | — | 0.23× | ||
| Q4 24 | — | 0.24× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.23× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $43.4M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $42.6M |
| 自由现金流率自由现金流/营收 | -142.8% | 131.8% |
| 资本支出强度资本支出/营收 | 0.0% | 2.5% |
| 现金转化率经营现金流/净利润 | — | 4.26× |
| 过去12个月自由现金流最近4个季度 | — | $73.5M |
8季度趋势，按日历期对齐
经营现金流DNARBB
| Q4 25 | $-47.7M | $43.4M | ||
| Q3 25 | $-31.6M | $2.1M | ||
| Q2 25 | $-40.3M | $21.7M | ||
| Q1 25 | $-51.5M | $7.8M | ||
| Q4 24 | $-42.4M | $58.5M | ||
| Q3 24 | $-103.5M | $24.5M | ||
| Q2 24 | $-84.4M | $11.7M | ||
| Q1 24 | $-89.3M | $4.8M |
自由现金流DNARBB
| Q4 25 | $-47.7M | $42.6M | ||
| Q3 25 | — | $1.8M | ||
| Q2 25 | $-40.3M | $21.6M | ||
| Q1 25 | $-59.1M | $7.6M | ||
| Q4 24 | $-56.1M | $57.7M | ||
| Q3 24 | $-118.6M | $24.2M | ||
| Q2 24 | $-111.4M | $11.5M | ||
| Q1 24 | $-96.0M | $4.7M |
自由现金流率DNARBB
| Q4 25 | -142.8% | 131.8% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | -81.2% | 60.2% | ||
| Q1 25 | -122.4% | 26.7% | ||
| Q4 24 | -128.0% | 201.0% | ||
| Q3 24 | -133.2% | 80.0% | ||
| Q2 24 | -198.2% | 42.0% | ||
| Q1 24 | -252.9% | 16.6% |
资本支出强度DNARBB
| Q4 25 | 0.0% | 2.5% | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.1% | 0.3% | ||
| Q1 25 | 15.8% | 0.6% | ||
| Q4 24 | 31.3% | 2.7% | ||
| Q3 24 | 16.9% | 0.8% | ||
| Q2 24 | 48.1% | 0.5% | ||
| Q1 24 | 17.7% | 0.5% |
现金转化率DNARBB
| Q4 25 | — | 4.26× | ||
| Q3 25 | — | 0.21× | ||
| Q2 25 | — | 2.32× | ||
| Q1 25 | — | 3.39× | ||
| Q4 24 | — | 13.34× | ||
| Q3 24 | — | 3.50× | ||
| Q2 24 | — | 1.61× | ||
| Q1 24 | — | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
RBB
暂无分部数据
